search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
137 new news items in the last 24 hours
  1. Home
  2. Health

The WHO recommends the use of GLP-1 medications, such as Ozempic and Wegovy, for obesity, but emphasizes the need for a healthy diet and exercise. Pharmaceutical companies are urged to reduce prices to expand access to these.

Raluca Ioana Draghici
whatsapp
facebook
linkedin
x
copy-link copy-link
1 December 2025, 17:27
main event image
Health
www.shutterstock.com
google-preference

Always see our news on Google

The World Health Organization (WHO) has recommended the use of GLP-1-based medications, such as Ozempic and Wegovy, in the treatment of obesity, emphasizing that they should be combined with a healthy diet, physical exercise, and medical monitoring. WHO has urged pharmaceutical companies to reduce prices and expand production to make these therapies accessible even in low-income countries. Although these medications are already well established in developed countries, WHO warns that global access remains limited, estimating that by 2030, less than 10% of people who could benefit from them will have access.

The new WHO therapeutic guideline includes a conditional recommendation for the use of GLP-1, considering the limited data on long-term efficacy and safety. WHO suggests differentiated pricing and voluntary licenses to allow other manufacturers to produce these medications. The expiration of patents for semaglutide, the active ingredient in Ozempic and Wegovy, will allow the emergence of generic medications, which could reduce prices. However, logistical challenges and the need to prepare health systems for the distribution of these medications remain significant obstacles.

Sources

sursa imagine
Digi24
OMS cere ca Ozempic și alte medicamente pentru slăbit să fie disponibile în toată lumea și explică modul corect de utilizare
sursa imagine
Politico Europe
Ozempic-style drugs should be available to all, not just the rich, says WHO

Latest News

19:34

Russia acknowledges that it has started to import fuels due to internal shortages. Details about the volumes and sources of the imports have not been provided.

19:24

Traffic in the Unirii Passage will be temporarily restricted for the next two nights for road tunnel cleaning works.

19:12

Deutsche Telekom acquires the operator Fiberhost and the provider Inea from Poland for approximately 1 billion euros, thus strengthening its position in the telecom market.

19:06

The North Beltway of Focșani will be opened to traffic starting Tuesday, August 25, providing a direct connection between DN2D and the A7 Motorway.

18:58

The mayor of Buzău announced that he will not run for a new term on behalf of the PSD / He is considering an independent candidacy.

See more news

NEWS ON THE SAME TOPICS

event image
International
The European Medicines Agency has recommended the approval of the Wegovy tablet, a weight loss medication from Novo Nordisk.
event image
Health
France will start partial reimbursement of treatments for obesity from June, thus becoming the first state in the EU to subsidize these medications.
event image
Health
Cats could benefit from weight loss medications. The first tests are already underway.
event image
International
France will start reimbursing weight loss medications from June 15, becoming the first European country to cover these treatments.
event image
EU
The European Commission is investigating Sanofi for the possible disparagement of a rival flu vaccine intended for vulnerable patients.
event image
Health
WHO begins clinical study for an antiviral drug against Ebola
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
WHO ozempic obesity treatment pharmaceutical companies

Editor’s Recommendations

main event image
Education
6 hours ago

SPECIAL Informat.ro / An additional exam at 14 years old: admission to high school, between performance and equal opportunities

main event image
Exclusive
5 hours ago
Original Content

Exclusively the Ministers' Monitor by NewsVibe: August 12-18, 2026

main event image Play button
8 hours ago
Podcast

PODCAST NewMoney / Cristian Busoi: We will take action against those who speculate on energy contracts for high prices

main event image
Exclusive
10 hours ago
Original Content

EXCLUSIVE | August 19, 2026. Trends in online searches / last 24 hours

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol